Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

Dan L. Eisenberg; Carol B. Toris; Carl B. Camras

doi:10.1016/S0039-6257(02)00327-2

Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

Dan L. Eisenberg, Carol B. Toris, Carl B. Camras

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

Original language	English (US)
Pages (from-to)	S105-S115
Journal	Survey of Ophthalmology
Volume	47
Issue number	4 SUPPL. 1
DOIs	https://doi.org/10.1016/S0039-6257(02)00327-2
State	Published - Aug 2002

Keywords

Bimatoprost
Glaucoma
Intraocular pressure
Latanoprost
Ocular hypertension
Timolol
Travoprost

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0039-6257(02)00327-2

Cite this

@article{3912e1223dc94a2a91b47136aea73f04,

title = "Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs",

abstract = "Bimatoprost (Lumigan{\texttrademark} [Allergan, Inc, Irvine CA]) and travoprost (Travatan{\texttrademark} [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.",

keywords = "Bimatoprost, Glaucoma, Intraocular pressure, Latanoprost, Ocular hypertension, Timolol, Travoprost",

author = "Eisenberg, {Dan L.} and Toris, {Carol B.} and Camras, {Carl B.}",

note = "Funding Information: Supported by the an unrestricted grant from Research to Prevent Blindness, Inc., New York, NY. Dr. Camras is a Research to Prevent Blindness Senior Scientific Investigator, and a consultant to the Pharmacia Corporation. The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. ",

year = "2002",

month = aug,

doi = "10.1016/S0039-6257(02)00327-2",

language = "English (US)",

volume = "47",

pages = "S105--S115",

journal = "Survey of Ophthalmology",

issn = "0039-6257",

publisher = "Elsevier Inc.",

number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Bimatoprost and travoprost

T2 - A review of recent studies of two new glaucoma drugs

AU - Eisenberg, Dan L.

AU - Toris, Carol B.

AU - Camras, Carl B.

N1 - Funding Information: Supported by the an unrestricted grant from Research to Prevent Blindness, Inc., New York, NY. Dr. Camras is a Research to Prevent Blindness Senior Scientific Investigator, and a consultant to the Pharmacia Corporation. The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PY - 2002/8

Y1 - 2002/8

N2 - Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

AB - Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

KW - Bimatoprost

KW - Glaucoma

KW - Intraocular pressure

KW - Latanoprost

KW - Ocular hypertension

KW - Timolol

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=0036668996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036668996&partnerID=8YFLogxK

U2 - 10.1016/S0039-6257(02)00327-2

DO - 10.1016/S0039-6257(02)00327-2

M3 - Article

C2 - 12204706

AN - SCOPUS:0036668996

SN - 0039-6257

VL - 47

SP - S105-S115

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

IS - 4 SUPPL. 1

ER -

Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this